$SNDX

Syndax Pharmaceuticals (SNDX) announced that its Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis (IPF) did not meet the primary endpoint of reducing lung function decline. The drug was well tolerated but will not be developed further for IPF. Ongoing trials in chronic graft-versus-host disease (cGVHD) continue, with results expected later this year and in early 2028. The company remains focused on advancing axatilimab and revumenib in other indications.

H.C. Wainwright reiterated a Buy rating and $38 price target for Syndax Pharmaceuticals (SNDX). The stock trades at $16.99 with a $1.52B market cap. Analysts cite potential of Niktimvo (axatilimab) for lung fibrosis. Q2 revenue rose 92% YoY to $72.8M but missed estimates. BofA lowered its target to $26, UBS to $33, while Jefferies kept a $35 target.

Syndax Pharmaceuticals (SNDX) reported strong growth for its lead drug, Revuforj, with $55 million in quarterly revenue and 85% market share in relapse-refractory AML. The company is advancing pivotal studies to expand Revuforj's use and developing a pipeline in lung cancer and myelofibrosis. Management highlighted Revuforj's potential peak revenue of over $2 billion, pending clinical and commercial success.

Syndax Pharmaceuticals (NASDAQ:SNDX) reported Q2 revenue of about $115 million, nearly doubling year over year, with Revuforj at $55 million (+91% YoY) and Niktimvo at $60 million (+67% YoY). Despite the growth, shares fell 2.41%. Management cited patient-start variability and ongoing profitability constraints, while pending Q4 data and pipeline updates remain key.

Syndax (SNDX) discussed its Q2 2026 earnings call, focusing on menin inhibitor Revuforj and axatilimab-related pipeline. Revuforj net revenue was $55 million, up 12% QoQ, with about 1,500 prescriptions, up 15% QoQ. Niktimvo Q2 net revenue rose to $60 million, up 67% YoY. The company reiterated expectations for Revuforj peak US net revenue above $2 billion.

Syndax Pharmaceuticals Inc (SNDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update • Total revenue of $73 million in 2Q26, a 92% year-over-year increase – • Revuforj ® (revumenib) net revenue of $54.7 million in 2Q26, a 91% year-over-year increase – – • Niktimvo™ (axa

Syndax Pharmaceuticals (SNDX) outlined plans to expand Revuforj (menin inhibition) into myelofibrosis, including a Q4 proof-of-principle phase 1/2 trial in about 30 patients. It also expects to file an IND for SNDX-62122 in 2027. Syndax and Incyte are advancing axatilimab (Niktimvo) in chronic GVHD and IPF, and introduced SNDX-4321 for EGFR-mutant NSCLC with an IND expected by year-end.

Metzger Michael A (Chief Executive Officer) sold 32,375 shares of Syndax Pharmaceuticals Inc (SNDX) at $24.24 ($0.78M total) on 2026-07-08 under a Rule 10b5-1 trading plan.

Botwood Nicholas A.J. (Head of R&D, CMO) sold 65,515 shares of Syndax Pharmaceuticals Inc (SNDX) at an average of $18.07 ($18.00–$18.14, $1.18M total) across 2 trades over 2026-06-11 to 2026-06-12 under a Rule 10b5-1 trading plan.

Syndax Pharmaceuticals reported multiple Revuforj (revumenib) abstracts at EHA 2026. In ROAR (R/R NPM1m/KMT2Ar), interim ORR was 82% (9/11) with 64% (7/11) CR/CRh. In SNDX-5613-0708 (newly diagnosed NPM1m/KMT2Ar), CRc was 97% (34/35) and MRD negativity 86% (25/29). Post-HSCT AUGMENT-101 analysis showed 12-month OS 95%. In SAVE (R/R AML), ORR was 88% (37/42) and MRD negativity 68% (25/37).